Summary: Dupilumab, a recombinant human IgG4 antibody, by inhibiting IL-4 and IL-13-dependent signaling pathways, multi-directionally blocks the inflammatory cascade, including the synthesis of other cytokines and mediators, cell influx, and the consequences of chronic ongoing processes in T2 inflammation. Clinical trial conducted in a group of patients diagnosed with severe asthma showed high efficacy and an optimal safety profile of dupilumab. A significant decrease in the frequency of exacerbations, improvement in respiratory function parameters, asthma control, quality of life was found. In cohorts of patients with steroid-dependent asthma, a decrease in the dose of oral corticosteroids was noticed. Real life studies confirmed the results of registration studies in our everyday clinical practice, and pharmacoeconomic analyzes clearly demonstrated the benefits for the payer after adding dupilumab to standard therapy in cases of severe uncontrolled asthma. Dupilumab is effective in a wide range of severe asthma phenotypes and endotypes, including allergic asthma, eosinophilic asthma, and asthma with comorbidities with a common mechanism of T2-mediated inflammation, such as atopic dermatitis or chronic sinusitis with nasal polyposis.